INSTRUCTIONS FOR USE HBsAg

VITROS Immunodiagnostic Products 843 5307

HBsAg Reagent Pack
VITROS Immunodiagnostic Products 142 1932
HBsAg Calibrator

Rx ONLY

Intended Use
For in vitro diagnostic use only.

VITROS Immunodiagnostic Products HBsAg Reagent Pack

For the qualitative detection of Hepatitis B Surface Antigen (HBsAg) in human serum and plasma (EDTA, heparin or citrate)
using the VITROS ECi/ECiQ/3600 Immunodiagnostic Systems and the VITROS 5600/XT 7600 Integrated Systems.

VITROS Immunodiagnostic Products HBsAg Calibrator

For use in the calibration of the VITROS ECi/ECiQ/3600 Immunodiagnostic Systems and the VITROS 5600/XT 7600
Integrated Systems for the qualitative detection of Hepatitis B Surface Antigen (HBsAg) in human serum and plasma
(EDTA, heparin or citrate).

Summary and Explanation of the Test

Hepatitis B is a major public health problem of global importance with an estimated 300 million persistent carriers of the
hepatitis B virus (HBV) worldwide. 1 Infection with HBV results in a wide spectrum of acute and chronic liver diseases.
Epidemiological studies have clearly linked the virus with the development of hepatocellular carcinoma. 2 HBV infection
produces an array of unique antigens and antibodies which follow distinct and individual serological patterns. By monitoring
these markers, it is possible not only to diagnose infection, but also to determine the stage of the disease and probable
prognosis. HBsAg is the first marker to appear following infection, and is the best indirect indicator of potentially infectious
sera.

Principles of the Procedure

An immunometric technique is used, this involves the simultaneous reaction of HBsAg in the sample with mouse
monoclonal anti-HBs antibody coated onto the wells and a horseradish peroxidase (HRP)-labeled mouse monoclonal anti-
HBs antibody in the conjugate. Unbound conjugate is removed by washing.
The bound HRP conjugate is measured by a luminescent reaction. 3 A reagent containing luminogenic substrates (a luminol
derivative and a peracid salt) and an electron transfer agent, is added to the wells. The HRP in the bound conjugate
catalyzes the oxidation of the luminol derivative, producing light. The electron transfer agent (a substituted acetanilide)
increases the level of light produced and prolongs its emission. The light signals are read by the system. The amount of
HRP conjugate bound is directly proportional to the concentration of HBsAg present in the sample.

Reaction Sample
Test Type System * Incubation Time Time to first result Test Temperature Volume
ECi/ECiQ, 3600,
Immunometric 29 minutes 37 minutes 37 °C 80 μL
5600, XT 7600
* Not all products and systems are available in all countries.

Version 9.1 Pub. No. GEM1200_XUS_EN 1 of 10

 HBsAg INSTRUCTIONS FOR USE
Warnings and Precautions

Reaction Scheme

Warnings and Precautions

WARNING: Potentially Infectious Material
Use caution when handling material of human origin. Consider all samples
potentially infectious. No test method can offer complete assurance that hepatitis
B virus, HCV, HIV 1+2 or other infectious agents are absent. Handle, use, store
and dispose of solid and liquid waste from samples and test components, in
accordance with procedures defined by appropriate national biohazard safety
guideline or regulation (e.g. CLSI document M29). 4
Human blood products provided as components of the VITROS HBsAg Reagent
Pack and VITROS HBsAg Calibrator have been obtained from donors who were
tested individually and who were found to be negative for antibodies to human
immunodeficiency virus (HIV 1+2) and hepatitis C virus (HCV), using approved
methods (enzyme immunoassays). Treat as if capable of transmitting infection.
The VITROS HBsAg Calibrator contains human HBsAg purified from donors who
were tested individually and who were found to be negative for antibodies to
human immunodeficiency virus (HIV 1+2) and hepatitis C virus (HCV), using
approved methods (enzyme immunoassays). The purified HBsAg has been heat
inactivated (10 hours at 60 °C [140 °F]). Treat as if capable of transmitting
infection.
WARNING: Contains Kathon or ProClin 200 (CAS 55965-84-9) 5
The VITROS HBsAg Reagent Pack and VITROS HBsAg Calibrator contain 1.0%
Kathon or ProClin 200. H317: May cause an allergic skin reaction. P280: Wear
protective gloves/protective clothing/eye protection/face protection. P302 + P352:
IF ON SKIN: Wash with plenty of soap and water. P333 + P313: If skin irritation
or rash occurs: Get medical advice/attention. P363: Wash contaminated clothing
before reuse.
Refer to www.Orthoclinicaldiagnostics.com for the Safety Data Sheets and for
Ortho contact information.

WARNING

Reagents
Reagent Pack Contents
1 reagent pack containing:
• 100 coated wells (mouse monoclonal anti-HBs, coated at 1 µg/well)
• 6.2 mL conjugate reagent (HRP-mouse monoclonal anti-HBs, 0.9 μg/mL) in buffer with bovine serum albumin, goat
serum and antimicrobial agent
• 8.4 mL assay reagent with human serum, calf serum, mouse serum and antimicrobial agent

2 of 10 Pub. No. GEM1200_XUS_EN Version 9.1

 INSTRUCTIONS FOR USE HBsAg
Specimen Collection, Preparation and Storage

Reagent Pack Handling

• The reagent pack is supplied ready for use.
• The reagent pack contains homogeneous liquid reagents that do not require shaking or mixing prior to loading onto the
system.
• Handle the reagent pack with care. Avoid the following:
– allowing condensation to form on the pack
– causing reagents to foam
– agitation of the pack

Reagent Pack Storage and Preparation

Reagent Storage Condition Stability
Unopened Refrigerated 2–8 °C (36–46 °F) expiration date
Opened On system System turned on ≤8 weeks
Opened Refrigerated 2–8 °C (36–46 °F) ≤8 weeks
• The VITROS HBsAg Reagent Pack is suitable for use until the expiration date on the carton when stored and handled as
specified. Do not use beyond the expiration date.
• Do not freeze unopened reagent packs.
• Load reagent packs directly from refrigerated storage to minimize condensation.
• Store opened refrigerated reagent packs in a sealed reagent pack storage box that contains dry desiccant.
• Exposure of Reagent Pack and Calibrator to temperatures >30 °C (86 °F) for extended periods of time may affect test
performance.

Calibrator Contents
• VITROS HBsAg Calibrator (human HBsAg ad subtype, inactivated 2 mL; 0.70±0.30 PEI Units* /mL) in buffer with bovine
serum albumin and antimicrobial agent
• Lot calibration card
• Protocol card
• 8 calibrator bar code labels
* Paul-Ehrlich-Institute HBsAg reference serum

Calibrator Handling
• Use only with reagent packs of the same lot number. Mix thoroughly by inversion and bring to 15–30 °C (59–86 °F)
before use. Each pack contains sufficient for a minimum of 6 determinations of each calibrator.
• Handle calibrators in stoppered containers to avoid contamination and evaporation. To avoid evaporation, limit the
amount of time calibrators are on the system. Refer to the operating instructions for your system. Return to 2–8 °C (36–
46 °F) as soon as possible after use, or load only sufficient for a single determination.

Calibrator Storage and Preparation

Calibrator Storage Condition Stability
Unopened Refrigerated 2–8 °C (36–46 °F) expiration date
Opened Refrigerated 2–8 °C (36–46 °F) ≤12 weeks
Opened Frozen ≤-20 °C (≤-4 °F) ≤12 weeks
• The VITROS HBsAg Calibrator is supplied ready for use.
• The VITROS HBsAg Calibrator is suitable for use until the expiration date on the carton when stored and handled as
specified. Do not use beyond the expiration date.
• Opened calibrators may be stored frozen (with no more than 1 freeze-thaw cycle).
• The VITROS HBsAg test uses 80 μL of calibrator for each determination. The VITROS HBsAg Calibrators may be used
directly on the VITROS Immunodiagnostic and VITROS Integrated Systems. Alternatively, transfer an aliquot of each
calibrator into a sample container (taking account of the minimum fill volume of the container), which may be bar coded
with the labels provided. For details on minimum fill volume of sample cups or containers, refer to the operating
instructions for your system.
• The VITROS HBsAg Calibrator is automatically processed in duplicate.

Specimen Collection, Preparation and Storage

Patient Preparation
No special patient preparation is necessary.

Version 9.1 Pub. No. GEM1200_XUS_EN 3 of 10

 HBsAg INSTRUCTIONS FOR USE
Testing Procedure

Specimens Recommended
• Serum
• EDTA plasma
• Heparin plasma
• Citrate plasma
Note: Results from citrate plasma samples will be proportionally lower due to dilution
by the liquid anticoagulant.

Specimens Not Recommended

Do not use turbid specimens. Turbidity in specimens may affect test results.

Special Precautions
IMPORTANT: Certain collection devices have been reported to affect other analytes and tests. 6
Owing to the variety of specimen collection devices available, Ortho Clinical
Diagnostics is unable to provide a definitive statement on the performance of its
products with these devices. Confirm that your collection devices are compatible
with this test.

Specimen Collection and Preparation

• Collect specimens using standard procedures. 7- 8
• Samples should be thoroughly separated from all cellular material. Failure to do so may lead to an erroneous result.
• Thoroughly mix samples by inversion and bring to 15–30 °C (59–86 °F) before use.
• The VITROS HBsAg test uses 80 μL of sample for each determination. This does not take account of the minimum fill
volume of the chosen sample container. For details on minimum fill volume of sample cups or containers, refer to the
operating instructions for your system.

Handling and Storage Conditions

• Handle samples in stoppered containers to avoid cross-contamination and evaporation. Use a separate disposable tip if
samples are manually pipetted. Avoid splashing, forming an aerosol, or cross-contaminating sample tube stoppers.
• The amount of time samples are on the system prior to analysis should be limited to avoid evaporation. Refer to the
operating instructions for your system.
• Return to 2–8 °C (36–46 °F) as soon as possible after use, or load sufficient volume for a single determination.
• Serum and plasma samples may be stored for up to 5 days at 2–8 °C (36–46 °F). Serum and plasma samples tested
initially and after 4 weeks storage at -20 °C (-4 °F) showed no performance differences.
• Avoid repeated freeze‑thaw cycles.

Testing Procedure
Materials Provided
• VITROS Immunodiagnostic Products HBsAg Reagent Pack
• VITROS Immunodiagnostic Products HBsAg Calibrator

Materials Required but Not Provided

• VITROS Immunodiagnostic Products Signal Reagent
• VITROS Immunodiagnostic Products Universal Wash Reagent
• Quality control materials such as VITROS Immunodiagnostic Products HBsAg Controls
• VITROS Immunodiagnostic Products Reagent Pack Storage Box (optional) with desiccant

Operating Instructions
Check the inventory regularly to aid the management of reagents and ensure that sufficient VITROS Signal Reagent,
VITROS Universal Wash Reagent and calibrated reagent lots are available for the work planned. When performing panels
of tests on a single sample, ensure that the sample volume is sufficient for the tests ordered.
For detailed information refer to the operating instructions for your system.
Note: Do not use visibly damaged product.

4 of 10 Pub. No. GEM1200_XUS_EN Version 9.1

 INSTRUCTIONS FOR USE HBsAg
Calibration

Default Test Name

The default test name which will appear on patient reports is HBsAg. The default short name that will appear on the test
selection menus and laboratory reports is HBsAg. These defaults may be reconfigured, if required. For detailed information
refer to the operating instructions for your system.

Calibration
Calibration Procedure
• Calibration is lot specific; reagent packs and calibrators are linked by lot number. Reagent packs from the same lot may
use the same calibration.
• A Master Calibration is established for each new reagent lot by performing multiple tests. This is the process by which a
lot-specific parameter [a] which links the signal at the cutoff (cutoff value) to the calibrator signal is determined.
Cutoff value = (a x Signal of Cal 1)
• Ensure that the Master Calibration for each new reagent lot is available on your system.
• Process the calibrator in the same manner as samples. Load sufficient for the automatic duplicate determination.
Calibration need not be programmed if bar code labels are used; Calibration will be initiated automatically.
• When the calibrator is processed the validity of the calibration is assessed against quality parameters which compares
the actual signal of the calibrator with the expected signal. If the calibration is acceptable the cutoff value is calculated
and stored for use with any reagent pack of that lot.
• The quality of calibration cannot be completely described by a single parameter. The calibration report should be used in
conjunction with acceptable control values to determine the validity of the calibration.
• Recalibration is required after a pre-determined calibration interval, or when a different reagent lot is loaded.
• Calibration results are assessed against a quality parameter. Failure to meet the defined quality parameter range will be
coded in the calibration report. For actions to be taken following a failed calibration, refer to the operating instructions for
your system.
Refer to the operating instructions for your system for detailed instructions on the calibration process.

When to Calibrate
• Calibrate when the reagent pack and calibrator lot changes.
• Calibrate every 28 days.
• After specified service procedures have been performed.
• If quality control results are consistently outside of your acceptable range.
For additional information on when to calibrate, refer to the operating instructions for your system.

Traceability of Calibration
The calibration of the VITROS HBsAg test is traceable to an in-house reference calibrator which has been value-assigned
to optimize the clinical sensitivity and specificity performance.

Calibration Model
Results are calculated as a normalized signal, relative to a cutoff value. During the calibration process a lot-specific
parameter is used to determine a valid stored cutoff value for the VITROS Immunodiagnostic and VITROS Integrated
Systems.

Quality Control
Quality Control Material Selection
VITROS HBsAg Controls are recommended for use with the VITROS Immunodiagnostic and VITROS Integrated Systems.
There are 2 VITROS HBsAg Controls (a negative control and a HBsAg positive control). The performance of other
commercial control fluids should be evaluated for compatibility with this test before they are used for quality control.
Control materials may show a difference when compared with other HBsAg methods if they contain high concentrations of
preservatives, stabilizers, or other nonphysiological additives, or otherwise depart from a true human sample matrix.
Appropriate quality control value ranges must be established for all quality control materials used with the VITROS HBsAg
test.

Quality Control Procedure Recommendations

• Good laboratory practice requires that controls be processed to verify the performance of the test.
• Choose control levels that check the clinically relevant concentrations.

Version 9.1 Pub. No. GEM1200_XUS_EN 5 of 10

 HBsAg INSTRUCTIONS FOR USE
Results

• To verify system performance, analyze control materials:

– After calibration
– According to local regulations or at least once each day that the test is being performed
– After specified service procedures are performed
If quality control procedures within your laboratory require more frequent use of controls, follow those procedures.
• Analyze quality control materials in the same manner as patient specimens.
• If control results fall outside your acceptable range, investigate the cause before deciding whether to report patient
results.
• Refer to the published guidelines for general quality control recommendations. 9
For more detailed information, refer to the operating instructions for your system.

Quality Control Material Preparation and Storage

Refer to the manufacturer’s product literature for preparation, storage, and stability information.

Results
Results are automatically calculated by the VITROS Immunodiagnostic and VITROS Integrated Systems.

Result Calculation
Results are calculated as a normalized signal, relative to the cutoff value. During the calibration process a lot-specific
parameter is used to determine a valid stored cutoff value for the VITROS Immunodiagnostic and VITROS Integrated
Systems.

Signal for test sample

Result =
Signal at the cutoff (cutoff value)

A result of ≥1.00 indicates a reactive sample and the possible presence of HBsAg.
A result of <0.90 indicates a non-reactive sample, negative for HBsAg.
A result of ≥0.90 and <1.00 indicates a borderline sample.

Interpretation of Results
A sample found borderline or reactive in the VITROS HBsAg test should be retested in duplicate to verify its status. Before
retesting, the sample should be centrifuged to ensure freedom from cells, cellular debris or fibrin. If results on repeat testing
are <0.90 for both replicates, the sample should be considered negative. If either duplicate retest result is ≥0.90, the
sample should be tested by supplemental tests to confirm the result. A repeatedly reactive sample confirmed by
supplemental tests should be considered positive for HBsAg. In the case of repeatedly borderline results, analysis of follow
up samples is recommended.

Expected Values
In a random blood donor population the number of samples found to be repeatedly reactive for HBsAg by the VITROS
HBsAg test was <0.1%. In a population of samples positive for HBsAg, 100% (400/400) were found to be reactive in the
VITROS HBsAg test.

Limitations of the Procedure

Known Interferences
The VITROS HBsAg test was evaluated for interference consistent with NCCLS Protocol EP7. 10 Commonly encountered
substances were tested on 2 lots of reagents. Of the compounds tested, none was found to interfere with the clinical
interpretation of the test. Refer to “Substances that do not Interfere” for a list of compounds tested that did not show
interference.

Other Limitations
• The results from this or any other diagnostic test should be used and interpreted only in the context of the overall clinical
picture.
• HBsAg results should only be used and interpreted in the context of the overall clinical picture. A negative test result
does not exclude the possibility of exposure to or infection with hepatitis B virus. Levels of HBsAg may be undetectable
both in early infection and late after infection. In rare cases HBsAg tests do not detect certain HBV mutant strains. 11

6 of 10 Pub. No. GEM1200_XUS_EN Version 9.1

 INSTRUCTIONS FOR USE HBsAg
Performance Characteristics

• Heterophilic antibodies in serum or plasma samples may cause interference in immunoassays. 12 These antibodies may
be present in blood samples from individuals regularly exposed to animals or who have been treated with animal serum
products. Results which are inconsistent with clinical observations indicate the need for additional testing.
• Do not use quality control materials preserved with azide.

Performance Characteristics
Sensitivity
Sensitivity was determined by testing serial dilutions of the WHO 2nd International Standard (NIBSC code 00/588) with 2
determinations using six reagent lots. The overall sensitivity of the VITROS HBsAg assay for the 2nd International Standard
was <0.10 IU/mL. A linear regression of the mean VITROS HBsAg result versus the calculated concentration of each
dilution was used to determine the HBsAg concentration at the cut-off. The mean value for the amount of HBsAg present at
the cut-off, determined as described above, was 0.080 IU/mL. The detection limit of the VITROS HBsAg test with the
Agence du Médicament SFTS 1996 Sensitivity Panel was <0.16 ng HBsAg/mL at the cutoff.
25 positive fresh serum and plasma samples, (≤1 day after sampling), were tested in direct comparison with a commercially
available CE-marked test. Both tests gave comparable results.

Specificity
Samples from 4013 presumed healthy blood donors, and 400 clinical samples were tested in the VITROS HBsAg test and
another commercially available test with the same intended use.

Samples Number of test samples Initially Reactive Repeatedly Reactive Confirmed Positive
Donor 4013 2 2 1
Clinical 400 0 0 0
The specificity for the VITROS HBsAg test for the donor samples was calculated as 99.98% (1/4012) based on repeat
reactives.

Potentially Cross-Reacting Subgroups

Additionally 192 samples from the following 9 potentially cross-reacting sub-groups were tested in the VITROS HBsAg test:
hepatitis A IgM, hepatitis B vaccine recipients, non viral liver diseases, HCV, HIV, CMV, EBV, SLE and rheumatoid factor
positive. Of these categories 4 out of the 192 samples were found to give reactive results in the VITROS HBsAg test. 2 of
these 4 samples were confirmed as positive for HBsAg. The remaining 2 samples could not be resolved by further testing
due to sample non-availability.

Precision
VITROS ECi/ECiQ Immunodiagnostic System
Precision was evaluated consistent with NCCLS document EP5. 13 2 replicates each of 4 freeze-dried control sera were
tested on 1 occasion per day on at least 20 different days. The experiment was performed using 2 reagent lots on 2
different systems. The data presented are a representation of the product performance.
VITROS 3600 Immunodiagnostic System and VITROS 5600 Integrated System
Precision was evaluated consistent with NCCLS document EP5. 14 2 replicates each of 2 freeze-dried control samples and
4 patient sample pools were tested on 2 separate occasions per day on at least 20 different days. The experiment was
performed using 1 reagent lot on each system. The data presented are a representation of the product performance.

Units= S/C (Ratio)

Mean VITROS Within-run* Within-calibration** Within-lab***
HBsAg S/C No. No.
System (Ratio) SD CV (%) SD CV (%) SD CV (%) Observ. Days
1.74 0.0301 1.7 0.0909 5.2 0.0896 5.1 48 24
ECi/ECiQ 2.32 0.0295 1.3 0.0963 4.2 0.0915 3.9 48 24
system 1 4.68 0.0773 1.7 0.202 4.3 0.197 4.2 48 24
6.63 0.0944 1.4 0.245 3.7 0.234 3.5 48 24
1.57 0.0426 2.7 0.0708 4.5 0.0929 5.9 48 24
ECi/ECiQ 2.21 0.0420 1.9 0.0843 3.8 0.0989 4.5 48 24
system 2 4.59 0.0770 1.7 0.151 3.3 0.179 3.9 48 24
6.34 0.140 2.2 0.242 3.8 0.283 4.5 48 24

Version 9.1 Pub. No. GEM1200_XUS_EN 7 of 10

 HBsAg INSTRUCTIONS FOR USE
References

Units= S/C (Ratio)

Mean VITROS Within-run* Within-calibration** Within-lab***
HBsAg S/C No. No.
System (Ratio) SD CV (%) SD CV (%) SD CV (%) Observ. Days
3.85 0.0932 2.4 0.129 3.4 0.129 3.3 96 24
0.08 0.00655 8.2 0.00811 10.1 0.00851 10.6 96 24
0.09 0.00412 4.6 0.00630 7.0 0.00654 7.3 96 24
3600
0.70 0.0306 4.4 0.0366 5.2 0.0386 5.4 92 23
1.45 0.0486 3.4 0.0701 4.8 0.0771 5.2 92 23
2.99 0.0739 2.5 0.0970 3.2 0.113 3.7 92 23
3.83 0.102 2.7 0.159 4.2 0.231 5.9 96 24
0.11 0.0175 15.9 0.0242 22.0 0.0264 24.0 96 24
0.10 0.00629 6.3 0.00895 9.0 0.0102 10.2 96 24
5600****
0.69 0.0166 2.4 0.0343 5.0 0.0429 6.0 92 23
1.42 0.0533 3.8 0.0604 4.3 0.0768 5.3 92 23
2.97 0.0766 2.6 0.0866 2.9 0.143 4.7 92 23
* Within-run (repeatability). Between Duplicate precision averaged over all runs
** Within-calibration. Total precision with weighted components of within-run, between–run and between-day variation
***Within-lab. A measure of the effect of recalibration on total precision, calculated within reagent lot, using data from at least 4
calibrations
**** Performance characteristics for the VITROS 5600 System are applicable to the VITROS XT 7600 System.

Substances that do not Interfere

The effect of Bilirubin, Hemoglobin and Triolein were tested in an HBsAg negative and an HBsAg positive sample. For each
substance, the highest concentration, which was considered not to impact the clinical interpretation of results, are shown in
the table below.

Compound Concentration
Bilirubin 0.342 mmol/L 20 mg/dL
Hemoglobin 0.310 mmol/L 500 mg/dL
Triolein 33.9 mmol/L 3000 mg/dL

References
1. Maynard JE et al. In Zuckermann AJ (ed), Viral Hepatitis and Liver Disease. Alan R Liss Inc: 967‑969 (1988) Control of
hepatitis B by Immunisation: Global Perspectives.
2. Beasley RP & Hwang L. In Vyas GN (ed), Viral Hepatitis and Liver Disease. Grune & Stratton, New York: 209‑224
(1984) Epidemiology of hepatocellular carcinoma.
3. Summers M et al. Clin Chem 41. S73 (1995) Luminogenic Reagent Using 3-Chloro 4-Hydroxy Acetanilide to Enhance
Peroxidase/Luminol Chemiluminscence.
4. CLSI. Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline - Fourth Edition.
CLSI document M29-A4. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
5. Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification,
labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC,
and amending Regulation (EC) No 1907/2006.
6. Calam RR. Specimen Processing Separator Gels: An Update. J Clin Immunoassay. 11:86–90; 1988.
7. CLSI. Collection of Diagnostic Venous Blood Specimens. 7th ed.CLSI standard GP41. Wayne, PA: Clinical and
Laboratory Standards Institute; 2017.
8. NCCLS. Procedures and Devices for the Collection of Diagnostic Capillary Blood Specimens; Approved Standard –
Fifth Edition. NCCLS document H4-A5 [ISBN 1-56238-538-0]. CLSI, 940 West Valley Road, Suite 1400, Wayne, PA
19087-1898 USA, 2004.
9. CLSI. Statistical Quality Control for Quantitative Measurements: Principles and Definitions; Approved Guideline - Third
Edition. CLSI document C24‑A3 [ISBN 1-56238-613-1]. CLSI, 940 West Valley Road, Suite 1400, Wayne, PA
19087-1898 USA, 2006.
10. NCCLS. Interference Testing in Clinical Chemistry; Proposed Guideline. NCCLS document EP7-P (ISBN
1-56238-020-6). CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087, 1986.
11. Carmen WF. Journal of Viral hepatitis, 1997; 4 (Suppl.1): 11‑20. The clinical significance of surface antigen variants of
hepatitis B virus.
12. Levinson SS. J Clin Immunoassay 15: 108‑115 (1992) The Nature of Heterophilic Antibodies and Their Role in
Immunoassay Interference.

8 of 10 Pub. No. GEM1200_XUS_EN Version 9.1

 INSTRUCTIONS FOR USE HBsAg
Glossary of Symbols

13. National Committee for Clinical Laboratory Standards. Order Code EP5-T2. (1992) Evaluation of Precision
Performance of Clinical Chemistry Devices - Second Edition.
14. NCCLS. Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline - Second
Edition. NCCLS document EP5‑A2 [ISBN 1-56238-542-9]. CLSI, 940 West Valley Road, Suite 1400, Wayne, PA
19087-1898 USA, 2004.

Glossary of Symbols

Revision History
Date of Revision Version Description of Technical Changes*
2019-09-06 9.1 • Glossary of Symbols: updated
• Added EC Representative address
2017-09-25 9.0 • Added information for the VITROS XT 7600 Integrated System
• Minor formatting and wording updates
• References: updated
• Glossary of Symbols: updated
* The change bars indicate the position of a technical amendment to the text with respect to the previous version of the document.

Version 9.1 Pub. No. GEM1200_XUS_EN 9 of 10

 HBsAg INSTRUCTIONS FOR USE
Revision History

When this Instructions For Use is replaced, sign and date below and retain as specified by local regulations or laboratory
policies, as appropriate.

Signature Obsolete Date

Conditions of supply: all supplies are made subject to the standard terms and conditions of Ortho Clinical
Diagnostics or its distributors. Copies of these are available on request.

0459
Ortho-Clinical Diagnostics
1500 Boulevard Sébastien Brant
B.P. 30335
67411 Illkirch
CEDEX, France

Ortho-Clinical Diagnostics
Felindre Meadows
Pencoed
Bridgend
CF35 5PZ
United Kingdom

VITROS is a trademark of Ortho Clinical Diagnostics.

© Ortho Clinical Diagnostics, 2005–2019

10 of 10 Pub. No. GEM1200_XUS_EN Version 9.1